Efficacy of Various Mitigation Devices in Reducing Fugitive Emissions from Nebulizers

References

1. 1.↵
   1. Simonds AK,
   2. Hanak A,
   3. Chatwin M,
   4. Morrell M,
   5. Hall A,
   6. Parker KH,
   7. et al

   . Evaluation of droplet dispersion during noninvasive ventilation, oxygen therapy, nebulizer treatment, and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess 2010;14(46):131-172.

   OpenUrlPubMed
2. 2.↵
   1. O'Neil CA,
   2. Li J,
   3. Leavey A,
   4. Wang Y,
   5. Hink M,
   6. Wallace M,
   7. et al

   ; Centers for Disease Control and Prevention Epicenters Program. Characterization of aerosols generated during patient care activities. Clin Infect Dis 2017;65(8):1335-1341.

   OpenUrlCrossRef
3. 3.↵
   1. Hui DS,
   2. Chow BK,
   3. Chu LCY,
   4. Ng SS,
   5. Hall SD,
   6. Gin T,
   7. et al

   . Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest 2009;135(3):648-654.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Judson SD,
   2. Munster VJ

   . Nosocomial transmission of emerging viruses via aerosol-generating medical procedures. Viruses 2019;11(10):940.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Jackson T,
   2. Deibert D,
   3. Wyatt G,
   4. Durand-Moreau Q,
   5. Adisesh A,
   6. Khunti K,
   7. et al

   . Classification of aerosol-generating procedures: a rapid systematic review. BMJ Open Resp Res 2020;7(1):e000730.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. van Doremalen N,
   2. Bushmaker T,
   3. Morris DH,
   4. Holbrook MG,
   5. Gamble A,
   6. Williamson BN,
   7. et al

   . Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382(16):1564-1567.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Chan VW,
   2. Ng HH,
   3. Rahman L,
   4. Tang A,
   5. Tang KP,
   6. Mok A,
   7. et al

   . Transmission of severe acute respiratory syndrome coronavirus 1 and severe acute respiratory syndrome coronavirus 2 during aerosol-generating procedures in critical care: a systematic review and meta-analysis of observational studies. Crit Care Med 2021;49(7):1159-1168.

   OpenUrl
8. 8.↵
   1. Halpin DMG,
   2. Criner GJ,
   3. Papi A,
   4. Singh D,
   5. Anzueto A,
   6. Martinez FJ,
   7. et al

   . The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2021;203(1):24-36.

   OpenUrlPubMed
9. 9.↵
   Respiratory Care Committee of Chinese Thoracic Society. Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020;43(4):288-296.

   OpenUrl
10. 10.↵
    1. Sethi S,
    2. Barjaktarevic IZ,
    3. Tashkin DP

    . The use of nebulized pharmacotherapies during the COVID-19 pandemic. Ther Adv Respir Dis 2020;14:1753466620954366.

    OpenUrl
11. 11.↵
    1. Woods JA

    . Evidence-based treatment during the SARS-CoV-2 pandemic: identifying the knowns and unknowns of nebulization. J Am Pharm Assoc (2003) 2021;61(2):e55-e56.

    OpenUrl
12. 12.↵
    1. McGrath JA,
    2. O’Sullivan A,
    3. Bennett G,
    4. O’Toole C,
    5. Joyce M,
    6. Byrne MA,
    7. et al

    . Investigation of the quantity of exhaled aerosols released into the environment during nebulization. Pharmaceutics 2019;11(2):75.

    OpenUrl
13. 13.↵
    1. Kaur R,
    2. Weiss T,
    3. Perez A,
    4. Fink JB,
    5. Chen R,
    6. Luo F,
    7. et al

    . Practical strategies to reduce nosocomial transmission to health care professionals providing respiratory care to patients with COVID-19. Crit Care 2020;24(1):571.

    OpenUrl
14. 14.↵
    1. Fink JB,
    2. Ehrmann S,
    3. Li J,
    4. Dailey P,
    5. McKiernan P,
    6. Darquenne C,
    7. et al

    . Reducing aerosol-related risk of transmission in the era of COVID-19: an interim guidance endorsed by the International Society of Aerosols in Medicine. J Aerosol Med Pulm Drug Deliv 2020;33(6):300-304.

    OpenUrlPubMed
15. 15.↵
    1. Li J,
    2. Fink JB,
    3. Elshafei AA,
    4. Stewart LM,
    5. Barbian HJ,
    6. Mirza SH,
    7. et al

    . Placing a mask on COVID-19 patients during high-flow nasal cannula therapy reduces aerosol particle dispersion. ERJ Open Res 2021;7(1):00519-2020.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Faul F,
    2. Erdfelder E,
    3. Buchner A,
    4. Lang AG

    . Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009;41(4):1149-1160.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Ramakrishnan S,
    2. Nicolau DV Jr.,
    3. Langford B,
    4. Mahdi M,
    5. Jeffers H,
    6. Mwasuku C,
    7. et al

    . Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomized controlled trial. Lancet Respir Med 2021;9(7):763-772.

    OpenUrl
18. 18.↵
    1. van Haren FMP,
    2. Richardson A,
    3. Yoon HJ,
    4. Artigas A,
    5. Laffey JG,
    6. Dixon B,
    7. et al

    . Inhaled nebulized unfractionated heparin for the treatment of hospitalized patients with COVID-19 (INHALE-HEP): protocol and statistical analysis plan for an investigator-initiated international meta-trial of randomized studies. Br J Clin Pharmacol 2021;87(8):3075-3091.

    OpenUrlPubMed
19. 19.↵
    1. Wu S,
    2. Huang J,
    3. Zhang Z,
    4. Wu J,
    5. Zhang J,
    6. Hu H,
    7. et al

    . Safety, tolerability, and immunogenicity of an aerosolized adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomized phase 1 clinical trial. Lancet Infect Dis 2021;S1473-3099(21)00396-0.
20. 20.↵
    1. O'Malley CA

    . Device cleaning and infection control in aerosol therapy. Respir Care 2015;60(6):917-927.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Tang JW,
    2. Kalliomaki P,
    3. Varila TM,
    4. Waris M,
    5. Koskela H

    . Nebulizers as a potential source of airborne virus. J Infect 2020;81(4):647-679.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Bem RA,
    2. van Mourik N,
    3. Klein-Blommert R,
    4. Spijkerman IJ,
    5. Kooij S,
    6. Bonn D,
    7. et al

    . Risk of aerosol formation during high-flow nasal cannula treatment in critically ill Subjects. Respir Care 2021;66(6):891-896.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Dhand R,
    2. Li J

    . Coughs and sneezes: their role in transmission of respiratory viral infections, including SARS-CoV-2. Am J Respir Crit Care Med 2020;202(5):651-659.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Li J,
    2. Jing G,
    3. Fink JB,
    4. Porszasz J,
    5. Moran E,
    6. Kiourkas R,
    7. et al

    . Airborne particulate concentrations during and after pulmonary function testing. Chest 2020;S0012-3692(20):35118-35117.

    OpenUrl
25. 25.↵
    1. Li J,
    2. Ehrmann S

    . High-flow aerosol dispersing- versus aerosol generating procedures. Am J Respir Crit Care Med 2020;202(8):1069-1071.

    OpenUrlCrossRefPubMed